Antibody Solutions

Company Info
Rep/Contact Info

Antibody Solutions

Accounting/Bookkeeping

Headquarters Location

Santa Clara

Number of Employees

-

About Us

Antibody Solutions is a privately held Contract Research Organization (CRO) based in Santa Clara, California, specializing in antibody discovery and development services. The company supports pharmaceutical, biotechnology, diagnostic, and academic research organizations by providing end-to-end solutions including antigen design, monoclonal and polyclonal antibody discovery, antibody engineering, manufacturing, and biological characterization. With over 25 years of experience, Antibody Solutions focuses on fit-for-purpose antibody development to help accelerate biologics from research to clinical stages.

John Kenney

About Me
With nearly 40 years of industry experience, John is recognized as one of the leading experts in the field of immunology and monoclonal antibody generation. When forming Antibody Solutions in 1995 with his wife, Judy Lynch-Kenney, John recognized not only the future potential of therapeutic antibodies in drug research, but also the inherent science- and business-related challenges in the emerging field. John set out to build a company that would improve access to the highest quality of antibody technology with a service model that provides discerning clients with bespoke, fit-for-purpose solutions and remarkable customer relations. John earned a doctorate degree in Pharmacology and Immunology at the Université Louis Pasteur (Strasbourg I) after completing undergraduate and graduate degrees in Microbiology at the University of South Florida. Before founding Antibody Solutions, John served as a research scientist and monoclonal antibody laboratory supervisor at Syntex Research. He has authored more than 40 publications and presents regularly at industry conferences and symposia.Notable scientific accomplishments include the discovery of five novel therapeutic candidates currently in clinical trials. John’s current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.